Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



GEN Poll

More »
May 28, 2012

Biotech M&A in 2012

What is your forecast for mergers and acquisitions this year?

Sunny and hot
 
  35.0%
Partly cloudy and lukewarm
 
  45.0%
Cloudy and cool
 
  15.0%
Undecided
 
  5.0%

Suggest a Poll
More Polls » View Results »

The bad news for the IPO market should mean good news for biotechnology M&As in 2012, and for the most part it does. However, premiums or multiples paid per deal vary significantly, with big companies increasingly willing to pay a big price for an increased presence in selected areas, notably specialty pharma and diagnostics. Not all deals go through, as the unsuccessful Roche-Ilumina and GSK-HGS courtships can attest. Experts expect M&As to continue the brisk pace of recent months through the rest of 2012.

GEN Poll

More » Poll Results » Archive »

Genome Sequencing and Patient Autonomy

Do you think ACMG’s recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy?

Suggest a Poll